Drugs / APL 400-003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001538 | Mar 1996 → Apr 2001 | AIDS | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00002350 | — | HIV infectious disease | Apollon | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APL 400-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002350 ↗ |
| Modality | Vaccine | “a plasmid DNA vaccine encoding the env and rev genes of HIV-1” NCT00001538 ↗ |
| Route | Intramuscular | “Patients are given intramuscular injections of APL 400-003” NCT00002350 ↗ |